The prices of protocol-defined exacerbations of asthma during the 24-week treatment period were estimated by dividing the full total number of this kind of exacerbations in each group over the course of the treatment period by the total patient-weeks at risk for the group. The first dose of study drug needed to be provided within 24 hours after randomization. For every patient, the weeks at risk had been computed by calculating the number of days between the initial administration of the study drug and the day of completion or termination of treatment and dividing that amount by 7 days.But the assumption that EHR development will mirror the cell phone’s trajectory offers three notable flaws. The EHR is definitely touted as a cost-saving, quality-promoting device, though cost-conserving projections have already been debunked and data on quality are combined.2 Although we’ve made improvement in patient safety only by carefully examining our errors, the hazards posed by technology are expected to right themselves somehow. Second, letting the marketplace shape usability assumes that clinicians are the focus on users. So EHRs will be only as good as the product quality metrics they’re designed to catch; technology can’t conquer fundamental measurement challenges.